StemCell Therapy

Portland, Oregon and Miami, Fla. (PRWEB) February 10, 2015

Global Stem Cells Group and the Regenerative Technology Alliance (RTA) have signed a memorandum of understanding to evaluate and promote stem cell training programs. RTA, a global provider of standards and certification for the emerging fields of regenerative medicine and science, will work with the Global Stem Cells Group to evaluate the regenerative medicine companys training programs and assess GSCGs participating physicians against the RTAs established international standards for the practice of regenerative and cell-based medicine.

Our new alliance with the RTA is a natural step toward establishing GSCGs recognition as a global leader in stem cell medicine, says Global Stem Cells Group CEO Benito Novas. This is a perfect fit for us, as Global Stem Cells Group shares the RTAs focus on high standards and transparency, especially when it comes to patient safety and advancing the field of stem cell medicine.

We are very pleased to have this alliance, says David Audley, General Secretary and Chair of the RTA. Our goal is to provide the highest level of transparency and oversight for the industry. Working with Global will allow us to have a direct and dramatic impact on physician training.

For more information, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup(dot)com, or call 305-224-1858.

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products, and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators, and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

About the RTA

The Regenerative Technology Alliance (RTA) a global provider of standards and certification for the emerging fields of regenerative medicine and science, is a 501(c)3 and is supported by donations from individuals, corporations and foundations to help advance its critical mission of bringing peer oversight and transparency to the field of cell-based and regenerative medicine.

For more information visit the RTA website, email david(at)regen-tech(dot)org, or call 503-446-5039.

Excerpt from:
Global Stem Cells Group Announces Alliance with Regenerative Technology

Cell Therapy, which is based in the Welsh capital Cardiff, says the medicine has the potential to reduce scarring of the heart muscle caused by a heart attack or failure.

Chief executive Ajan Reginald, who was previously at Roche, said crowd funding was a quick way to raise money for final stage trials or commercial launches.

Loading article content

"It was very fast and very efficient," he said. "We have spent five per cent of our time on fundraising, which enables me to spend 95 per cent of my time on the business."

The company's founder Martin Evans shared the 2007 Nobel Prize for medicine for groundbreaking stem cell research.

Cell Therapy used website Crowdcube to raise nearly three times its original target from more than 300 investors.

Mr Reginald said the backers included investment bankers, hedge fund employees and scientists.

"Crowd funding allows investors to look in detail at a company in their own time," he said, adding that some 10,000 investors had seen the pitch.

The company plans to publish data from clinical trials of the drug, called Heartcel, next month, before final stage trials with a view to a launch in 2016.

See more here:
Biotech firm Cell Therapy claims crowdfunding record with heart drug

Contact Information

Available for logged-in reporters only

Newswise The governing board of the California Institute for Regenerative Medicine (CIRM) has awarded two University of California, San Diego researchers almost $3 million in combined funding to pursue new technologies intended to accelerate advances moving stem cell therapies out of the lab and into the clinic.

The funding was part of almost $30 million in new Tools and Technologies awards announced at CIRMs monthly meeting in San Francisco.

Sometimes even the most promising therapy can be derailed by a tiny problem, said Jonathan Thomas, JD, PhD, chair of the CIRM Board. These awards are designed to help find ways to overcome those problems, to bridge the gaps in our knowledge and ensure that the best research is able to keep progressing and move out of the lab and into clinical trials in patients.

Shaochen Chen, PhD, professor in the Department of Nanoengineering in the Jacobs School of Engineering and a member of the Institute of Engineering in Medicine at UC San Diego, received a $1.3 million in CIRM funding for development of 3D bioprinting techniques using human embryonic stem cell-derived heart muscle cells to create new cardiac tissue.

Millions of Americans suffer from cardiovascular disease, specifically congestive heart failure in which a heart valve ceases to work properly. Current treatment often calls for a valve transplant, but donor availability does not meet need.

Chen and colleagues are exploring the possibility of engineering healthy cardiac tissues bioprinted from heart muscle cells, called cardiomyocytes, created from human embryonic stem cells. These tissues could then be implanted in a damaged heart, restoring function.

Shyni Varghese, PhD, associate professor in the Department of Bioengineering at the Jacobs School of Engineering and director of the Bio-Inspired Materials and Stem Cell Engineering Laboratory, received a $1.4 CIRM grant to improve in vivo function of transplanted stem cells.

Vargheses lab focuses upon the complex interactions of cells with their surrounding microenvironment, and how the conditions necessary to promote normal, healthy survival and growth occur.

Read the original:
Two UC San Diego Scientists Receive Stem Cell Technology Grants

Contact Information

Available for logged-in reporters only

Newswise Two scientists from the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have received a California Institute of Regenerative Medicine (CIRM) Tools and Technology Award that will forward revolutionary stem cell medicine. The UCLA researchers were among only 20 scientists nationwide to receive the Tools and Technologies Award, the most of any institution represented.

Recipients receiving awards for their respective projects included Dr. James Dunn, professor of bioengineering and surgery, for his research investigating skin-derived precursor stem cells for the treatment of enteric neuromuscular dysfunction, and Dr. Hanna Mikkola, associate professor of molecular, cell and developmental biology, for her work creating a suite of engineered human pluripotent stem cell lines to facilitate the generation of patient specific hematopoietic stem cells.

UCLA Broad Stem Cell Research Center Director Owen Witte said, We are very grateful for CIRMs support of these potentially groundbreaking projects intended to overcome significant bottlenecks in driving stem cell therapies to the clinic.

The CIRM Tools and Technologies initiative is designed specifically to support research that can address regenerative medicines unique translational challenges. The award seeks to facilitate the creation, design and testing of broadly applicable novel tools and technologies for addressing translational bottlenecks to stem cell therapies.

Dr. James Dunn: Unlocking the Secrets of Neuromuscular Dysfunction

Dr. Dunns cutting-edge work focuses on assessing the therapeutic potential of skin-derived stem cells to treat neuromuscular gastrointestinal diseases. CIRM reviewers noted that, if successfully completed, the project would likely have a major impact upon the field. His lab will develop a model of intestinal neuromuscular dysfunction that is amenable to stem cell transplantation.

Dunns novel approach to treat these patients will use stem cells reprogrammed from the patients own skin (induced pluripotent stem cells) to generate the neural system to correct the intestinal dysfunction. Dunn and his team hope the research will result in a clinical trial using patient specific induced pluripotent stem cells and provide a critical step toward an improved therapeutic approach and to treat intestinal neuromuscular dysfunction.

Dr. Dunns research was additionally supported by the National Institutes and Sun West Company.

Read the original post:
UCLA Researchers Receive Prestigious CIRM Tools and Technologies Award

MIAMI (PRWEB) January 30, 2015

Regenestem Network has announced the grand opening of a new stem cells clinic in the prestigious Hospital Clinica de Merida in Yucatan, Mexico. The new clinic will operate under the direction of Gilberto Hernandez Falcon, M.D., a member of the Global Stem Cells Advisory Board and CEO of Regenestem Mexico Sur in Villahermosa Tabasco.

The Yucatan facility is the newest in a growing number of Regenestem clinics providing comprehensive regenerative medicine services worldwide. Plans include equipping the new clinic with the latest technology from the Adilyfe line of stem cell treatment products, made available through Global Stem Cells Group affiliate Adimarket.

Expanding the Regenestem Network throughout Mexico is a great opportunity to bring cutting edge medical advancements to patients, while creating and sustaining new jobs for medical professionals in the Central America region, says Regenestem Founder and CEO Ricardo DeCubas. Were proud to be working with Dr. Hernandez Falcon in making stem cell medicine available to a growing number of patients in the region.

The new Regenestem Yucatan facility will offer the most advanced protocols and techniques available in stem cell medicine.

I am proud to continue to provide stem cell therapies to a wide range of patients here in Mexico and the Central America region, Hernandez Falcon says. Working with the Regenestem Network and Global Stem Cells Group has allowed us to help more and more patients access promising treatments for a range of medical problems.

The Global Stem Cells Group and Regenestem are committed to the highest of standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

For more information, visit the Regenestem Network website, email info(at)regenstem(dot)com, or call 305-224-1858.

About Regenestem:

Regenestem Network, a division of the Global Stem Cells Group, Inc., is an international medical practice association committed to researching and producing comprehensive stem cell treatments for patients worldwide. Having assembled a highly qualified staff of medical specialistsprofessionals trained in the latest cutting-edge techniques in cellular medicineRegenestem continues to be a leader in delivering the latest protocols in the adult stem cell arena. Global Stem Cells Group and Regenestem Network are expanding the companys clinical presence worldwide by partnering with experienced and qualified regenerative medicine physicians to open new clinics licensed and developed under the Regenestem banner. In 2014, Global Stem Cells Group expanded the Regenestem Networks global presence to 20 countries.

See the article here:
Regenestem Network and Gilberto Hernandez Falcon, M.D. Open Stem Cell Clinic in Yucatan

Sheryl Ubelacker, The Canadian Press Published Thursday, January 29, 2015 6:49AM EST

TORONTO -- Gordie Howe's son says the hockey legend's stroke symptoms have improved since his treatment with stem cells at a Mexican clinic in early December and he wants him to repeat the procedure.

But regenerative medicine experts say there's no scientific evidence such therapies work, and in some cases they can be seriously harmful or even deadly.

The 86-year-old Howe suffered two disabling strokes late last year. In December, the family took him to a Tijuana clinic where he received stem cell injections as part of a clinical trial being run under a licensing agreement with Stemedica Cell Technologies of San Diego, Calif.

The experimental treatment involved injecting neural stem cells into Howe's spinal canal, along with intravenous infusions of mesenchymal stem cells, which are found in bone marrow, fat and umbilical cord blood.

Marty Howe said his father can walk again, his speech is improving and he is regaining some of the weight he lost following the strokes.

"After his stem cell treatment, the doctor told us it was kind of an awakening of the body, and it was all that," he told The Canadian Press while in Calgary for a hockey promotion event Tuesday. "They call it the miracle of stem cells and it was nothing less than a miracle."

However, experts in the field question whether stem cells are responsible for Howe's improvement and caution that most so-called stem cell therapies have not gone through rigorous scientific trials, nor have they been approved as treatments by Health Canada or the U.S. Food and Drug Administration.

Mick Bhatia, director of McMaster University's Stem Cell and Cancer Research Institute, said there are many unknowns in Howe's case, such as how many stem cells were administered, were tests done to see whether they migrated to the targeted area of the body, and did they take up residence where they might have some effect or simply disappear?

"Is this a transient effect, or is it really a perceived or somewhat of a placebo effect and is there something really happening? Scientifically and biologically that is important," Bhatia said Wednesday from Hamilton.

Originally posted here:
Gordie Howe's stem cell therapy raises concerns among medical experts

TORONTO - Gordie Howe's son says the hockey legend's stroke symptoms have improved since his treatment with stem cells at a Mexican clinic in early December and he wants him to repeat the procedure.

But regenerative medicine experts say there's no scientific evidence such therapies work, and in some cases they can be seriously harmful or even deadly.

The 86-year-old Howe suffered two disabling strokes late last year. In December, the family took him to a Tijuana clinic where he received stem cell injections as part of a clinical trial being run under a licensing agreement with Stemedica Cell Technologies of San Diego, Calif.

The experimental treatment involved injecting neural stem cells into Howe's spinal canal, along with intravenous infusions of mesenchymal stem cells, which are found in bone marrow, fat and umbilical cord blood.

Marty Howe said his father can walk again, his speech is improving and he is regaining some of the weight he lost following the strokes.

"After his stem cell treatment, the doctor told us it was kind of an awakening of the body, and it was all that," he told The Canadian Press while in Calgary for a hockey promotion event Tuesday. "They call it the miracle of stem cells and it was nothing less than a miracle."

However, experts in the field question whether stem cells are responsible for Howe's improvement and caution that most so-called stem cell therapies have not gone through rigorous scientific trials, nor have they been approved as treatments by Health Canada or the U.S. Food and Drug Administration.

Mick Bhatia, director of McMaster University's Stem Cell and Cancer Research Institute, said there are many unknowns in Howe's case, such as how many stem cells were administered, were tests done to see whether they migrated to the targeted area of the body, and did they take up residence where they might have some effect or simply disappear?

"Is this a transient effect, or is it really a perceived or somewhat of a placebo effect and is there something really happening? Scientifically and biologically that is important," Bhatia said Wednesday from Hamilton.

And because Howe received adult stem cells produced from donor cells, he may have needed to take drugs to prevent an immune reaction as well as anti-inflammatory medications, he said.

Visit link:
Gordie Howe's stem cell therapy raises concerns among experts

MIAMI (PRWEB) January 29, 2015

Regenestem Network, the worlds largest membership network of regenerative medicine practitioners, has announced the launch of a new stem cell clinic in Oaxaca, Mexico. The new facility, offering the most advanced cellular medicine protocols and techniques available is in partnership with Ulises Cervera, M.D. a neurologist coming from the Children's Hospital of Morelia, Mexico.

The new Oaxaca facility will offer the most advanced protocols and techniques available in stem cell medicine to patients from across Mexico and around the world.

Global Stem Cells Group and Regenestem Network are expanding the companys clinical presence worldwide by partnering with experienced and qualified regenerative medicine physicians to open new clinics licensed and developed under the Regenestem banner.

In 2014, Global Stem Cells Group expanded the Regenestem Networks global presence to 20 countries.

Regenestem offers stem cell treatments to help treat a variety of diseases and conditions including arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes, and pain due to injuries at various facilities worldwide. Regenestem Oaxaca will have an international staff experienced in administering the latest in cellular therapies.

Regenestem is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Regenestem clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.

The Global Stem Cells Group and Regenestem are committed to the highest of standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

For more information, visit the Regenestem Network website, email info(at)regenstem(dot)com, or call 305-224-1858.

About Regenestem: Regenestem Network, a division of the Global Stem Cells Group, Inc., is an international medical practice association committed to researching and producing comprehensive stem cell treatments for patients worldwide. Having assembled a highly qualified staff of medical specialistsprofessionals trained in the latest cutting-edge techniques in cellular medicineRegenestem continues to be a leader in delivering the latest protocols in the adult stem cell arena.

View original post here:
Global Stem Cells Group and Regenestem Network Announce Launch of New Stem Cell and Regenerative Medicine Clinic in ...

Boston, MA (PRWEB) January 29, 2015

Dr. James Sherley, Director of the new biotech start-up Asymmetrex, LLC (formerly known as The Adult Stem Cell Technology Center, LLC) is looking forward to four upcoming opportunities in 2015 to continue to impress both academic and industry audiences with his companys very frank take on what is needed to accelerate progress in stem cell medicine.

Asymmetrex has set the focus for its efforts on adult stem cells that are found in the organs and tissues of children and adults. Unlike human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), adult stem cells are free of induced mutations, are not tumor-forming, and have the essential ability to continuously regenerate mature human tissue cells like those in children and adults. To date, hESCs and iPSCs have only been able to regenerate immature cells, and even those not continuously.

Previously, the two main challenges hindering wider use of adult stem cells for drug development and medical therapies have been difficulty producing them and difficulty counting them. Asymmetrex has reported, and in many cases secured patents for, new technologies that reduce or eliminate both of these challenges. At the coming conferences, Dr. Sherley will describe the companys most recent technological advances in this regard and discuss the science that led to them.

In particular, he will highlight the companys newest technology developed with partner AlphaSTAR Corporation for estimating adult stem cell number in any human tissue. The two companies are developing the new technology as an assay to detect drug candidates that will fail in expensive pre-clinical animal studies and clinical trials because of intolerable toxicity against tissue stem cells. By screening-out such drugs earlier in the drug development process, Asymmetrex and AlphaSTAR estimate that together they could save the U.S. pharmaceutical industry $4-5 billion each year.

The four scheduled conferences include the 7th Annual Predictive Toxicology Summit, February 16-18, in London; the 5th World Congress on Cell and Stem Cell Research, March 23-25, in Chicago; the 2015 Annual Meeting at Experimental Biology, March 28-April 1, in Boston; and the Inaugural 3D Cellular Models Conference, June 11-12, also in Boston.

The breadth of conference topics reflects the many important roles that adult tissue stem cells play in human biology and cellular medicine. Dr. Sherley offers that, Because of the importance of adult stem cells in normal body function, it is not surprising that Asymmetrexs technologies impact so many different facets of stem cell biology, regenerative medicine, and drug development.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrexs founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrexs focus is employing its technological advantages to develop facile methods for monitoring adult stem cell number and function in clinically important human tissues.

See more here:
Asymmetrex Scheduled to Present Unique Perspectives in Stem Cell Biology and Recent Advances in Technologies for Adult ...

IMAGE:CDK6 is needed for leukemic stem cell activation (left). When CDK6 is absent, the LSC remains in a quiescent state and leukemia formation is prohibited (right). view more

Credit: Angelika Berger / Vetmeduni Vienna

Despite enormous progress in cancer therapy, many patients still relapse because their treatment addresses the symptoms of the disease rather than the cause, the so-called stem cells. Work in the group of Veronika Sexl at the University of Veterinary Medicine, Vienna has given a tantalizing clue to a solution. In the current issue of Blood, the scientists report that the cell-cycle kinase CDK6 is required for activation of the stem cells responsible for causing leukemia.

Hematopoietic stem cells (HSCs) are normally inactive, i.e. quiescent. When new blood cells are needed, for example to replace blood that has been lost, HSCs start to multiply and develop into mature blood cells. If the process is initiated at an inappropriate time, hematopoietic diseases such as leukemia may result and leukemic stem cells may develop. These represent a major challenge to leukemia therapy: they are quiescent and thus protected from elimination by the immune system and from treatment such as chemotherapy. Leukemic stem cells frequently cause relapse in cancer patients, often years or even decades after an apparently successful treatment.

Working with stem cells isolated from mice, Ruth Scheicher and colleagues at the University of Veterinary Medicine, Vienna have investigated possible differences between leukemic stem cells and the healthy stem cells in the body. They looked in particular at the function of the CDK6 protein, which is known to be involved in controlling the cell cycle. Surprisingly, CDK6 was also found to regulate the activation of hematopoietic and leukemic stem cells, which it does by inhibiting the transcription factor Egr1. Upon loss of CDK6, Egr1 becomes active and prevents stem cells from dividing. In a further twist to the tale, the mechanism operates only when hematopoietic stem cells are stressed, e.g. in leukemia, and not in the normal physiological situation.

Scheicher is quick to note the significance of her finding. "CDK6 is absolutely necessary for leukemic stem cells to induce disease but plays no part in normal hematopoiesis. We thus have a novel opportunity to target leukemia at its origin. Inhibiting CDK6 should attack leukemic stem cells while leaving healthy HSCs unaffected".

###

Service: The article 'CDK6 as a key regulator of hematopoietic and leukemic stem cell activation' by Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan AS, Prchal-Murphy M, Heller G, Schneckenleithner C, Salazar-Roa M, Zchbauer-Mller S, Zuber J, Malumbres M, Kollmann K and Sexl V. was published in the journal Blood. http://www.bloodjournal.org/content/125/1/90.long?sso-checked=true

About the University of Veterinary Medicine, Vienna

The University of Veterinary Medicine, Vienna in Austria is one of the leading academic and research institutions in the field of Veterinary Sciences in Europe. About 1,300 employees and 2,300 students work on the campus in the north of Vienna which also houses five university clinics and various research sites. Outside of Vienna the university operates Teaching and Research Farms. http://www.vetmeduni.ac.at

Read more:
Keeping the Kraken asleep

Pluripotent stem cells are cells capable of indefinite expansion and then differentiation into any and all of the cell types of the human body. Examples of pluripotent stem cells are human embryonic stem cells (hES) and induced pluripotent stem (iPS) cells. These stem cells potentially offer a new technology platform for the manufacture of a wide array of cell types designed to be transplanted into the body to restore healthy tissue function.

BioTime and its subsidiaries are focused on developing and commercializing a broad portfolio of innovative cellular therapeutics and diagnostic products, while also continuing to build value in other ways, such as through the addition of new patents to our industry-leading intellectual property estate, said Dr. Michael D. West, Ph.D., BioTimes Chief Executive Officer. We are making significant strides in patenting our core platform of pluripotent stem cell technology and strengthening our competitive position in regenerative medicine. For the first time in history, pluripotent stem cells offer a means of manufacturing previously rare and valuable human cell types in a cost-effective manner and on an industrial scale. We plan to utilize our strengthened patent position to drive value for our shareholders as the field of regenerative medicine begins to address the large and growing markets associated with chronic and age-related degenerative disease.

New Patents Owned by BioTime or one of its subsidiaries:

European patent 1809739 This issued patent claims cell culture media for the proliferation and scale-up of hES cells. The patent issuing in Austria, France, Germany, Ireland, Switzerland and Sweden provides a propagation medium for culturing hES cells in the laboratory such that the cells proliferate without differentiating as defined in the claims. The technology allows the user to rapidly produce high-quality embryonic stem cells for use in therapy and drug discovery, in a cost-effective and controlled manner, from defined or commercially available reagents. The patent is therefore useful for manufacturing products from hES cells. Patents in the same family have previously issued in the United States, Australia, UK, Israel, Singapore and Hong Kong, with additional applications pending.

Canada patent 2559854 and China patent ZL200580008779.0 These patents claim a differentiation method for making high purity heart muscle preparations from pluripotent stem cells such as hES cells suitable for use in regenerative medicine. The issued claims cover methods wherein the pluripotent stem cells are treated with specific growth factors and differentiation conditions to manufacture beating heart muscle cells. The patents are therefore useful in the manufacture and commercialization of heart muscle cells for research, for the testing of drugs on the heart, and potentially for regenerating heart muscle following a heart attack or heart failure. Patents in the same family have previously issued in the United States, Australia, UK, Israel, Japan and Singapore, with additional applications pending.

South Korea patent1543500B The patent titled, Hematopoietic Cells from Human Embryonic Stem Cells, claims methods for using pluripotent stem cell technology for inducing immune tolerance of cells transplanted into a patient (that is, in helping to prevent the rejection of transplanted cells). As such, the patent claims may be useful in commercializing diverse types of transplantable cells. Patents in the same family have previously issued in Australia, UK, Israel, Japan and Singapore, with additional applications pending.

Canada patent 2468335 The patent describes cartilage-forming cells derived from human pluripotent stem cells such as hES cells. The claims in the patent relate to a system of making the cartilage-forming cells using factors of the transforming growth factor beta (TGF-beta) family, of immortalizing the cells with the human telomerase gene, pharmaceutical formulations of the cells for therapeutic use in arthritis, as well as other claims. The patent is therefore useful for the manufacture of such cells for use in research and potentially in therapy for a number of applications in orthopedic medicine. Patents in the same family have previously issued in the United States, Australia, Singapore, Israel and South Korea, with additional applications pending.

Israel patent208116 The patent titled, Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells, claims methods for the manufacture of dendritic cells from primate pluripotent stem cells. Dendritic cells are cells that trigger an immune response to a particular molecule. Often their role is to stimulate the immune system to attack microorganisms such as bacteria. BioTimes subsidiary Asterias Biotherapeutics is developing hES cell-derived dendritic cells modified to trigger an immune response to specific antigens related to cancer. A patent in the same family has previously issued in the United States, with additional applications pending.

Singapore patent 188098 The patent titled, Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes, claims certain polymers upon which heart muscle cells derived from pluripotent stem cells may be cultured. The patent is potentially useful for the manufacture of human heart muscle cells for drug screening and toxicity testing and for use in the manufacture of such cells for transplantation into human subjects for the treatment of heart disease. A patent in the same family has previously issued in the United States, with additional applications pending.

Singapore patent 176957 The patent titled, Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes, claims methods for the purification of pluripotent stem cell-derived oligodendrocytes by the removal of contaminating cells that display an antigen called epithelial cell adhesion molecule (EpCAM). This method is potentially useful in the purification of such oligodendrocytes prior to their use in research or human therapy. Patents in the same family have previously issued in the United States and China, with additional applications pending.

Read more from the original source:
BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer ...

The Villages, Florida (PRWEB) January 22, 2015

The Miami Stem Cell Treatment Center announces the opening of a new office in The Villages, Florida on January 28, 2015, with Dr. Thomas A. Gionis, Surgeon-in-Chief and Dr. Nia Smyrniotis, Medical Director and Surgeon.

Their new office is located at the Villages Endoscopy & Surgical Center, 10900 SE 174th PL. Rd., Summerfield, FL 34491. If you have any questions or would like further information please call us at (561) 331-2999.

The Miami Stem Cell Treatment Center (Miami; Boca Raton; Orlando; and now The Villages), along with sister affiliates, the Irvine Stem Cell Treatment Center (Irvine; Westlake Villages, Ca.) and the Manhattan Regenerative Medicine Medical Group (Manhattan, New York), abide by approved investigational protocols using adult adipose derived stem cells (ADSCs) which can be deployed to improve patients quality of life for a number of chronic, degenerative and inflammatory conditions and diseases. ADSCs are taken from the patients own adipose (fat) tissue (found within a cellular mixture called stromal vascular fraction (SVF)). ADSCs are exceptionally abundant in adipose tissue. The adipose tissue is obtained from the patient during a 15 minute mini-liposuction performed under local anesthesia in the doctors office. SVF is a protein-rich solution containing mononuclear cell lines (predominantly adult autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important Growth Factors that facilitate the stem cell process and promote their activity.

ADSCs are the bodys natural healing cells - they are recruited by chemical signals emitted by damaged tissues to repair and regenerate the bodys injured cells. The Miami Stem Cell Treatment Center only uses Adult Autologous Stem Cells from a persons own fat no embryonic stem cells are used; and no bone marrow stem cells are used. Current areas of study include: Emphysema, COPD, Asthma, Heart Failure, Heart Attack, Parkinsons Disease, Stroke, Traumatic Brain Injury, Lou Gehrigs Disease, Multiple Sclerosis, Lupus, Rheumatoid Arthritis, Crohns Disease, Muscular Dystrophy, Inflammatory Myopathies, and degenerative orthopedic joint conditions (Knee, Shoulder, Hip, Spine). For more information, or if someone thinks they may be a candidate for one of the adult stem cell protocols offered by the Miami Stem Cell Treatment Center, they may contact Dr. Gionis or Dr. Smyrniotis directly at (561) 331-2999, or see a complete list of the Centers study areas at: http://www.MiamiStemCellsUSA.com.

About the Miami Stem Cell Treatment Center: The Miami Stem Cell Treatment Center, along with sister affiliates, the Irvine Stem Cell Treatment Center and the Manhattan Regenerative Medicine Medical Group, is an affiliate of the California Stem Cell Treatment Center / Cell Surgical Network (CSN); we are located in Boca Raton, Orlando, Miami and now The Villages, Florida. We provide care for people suffering from diseases that may be alleviated by access to adult stem cell based regenerative treatment. We utilize a fat transfer surgical technology to isolate and implant the patients own stem cells from a small quantity of fat harvested by a mini-liposuction on the same day. The investigational protocols utilized by the Miami Stem Cell Treatment Center have been reviewed and approved by an IRB (Institutional Review Board) which is registered with the U.S. Department of Health, Office of Human Research Protection (OHRP); and our studies are registered with Clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH). For more information, visit our websites: http://www.MiamiStemCellsUSA.com, http://www.IrvineStemCellsUSA.com, or http://www.NYStemCellsUSA.com.

Follow this link:
The Miami Stem Cell Treatment Center Announces the Opening of a New Office in The Villages

MIAMI (PRWEB) January 22, 2015

Regenestem, a division of the Global Stem Cells Group, Inc., has announced the launch of a new stem cell treatment center in Veracruz, Mexico. The new facility offers the most advanced protocols and techniques in cellular medicine to patients from around the world.

The opening of Regenestem Veracruz is in partnership with Eleuterio Arrieta, M.D., Director of Santa Teresita Hospital in Veracruz. Dr. Arrieta has extensive experience in management of chronic degenerative diseases with autologous stem cell therapies, expertise he will use to deliver cutting edge therapies and follow-up treatment under the Regenestem brand in Veracruz.

Under the direction of Global Stem Cells Group, Regenestem is expanding its clinical presence worldwide by partnering with qualified physicians experienced in stem cell therapies to open new clinics, licensed and developed under the Regenestem banner.

In 2014, Global Stem Cells Group expanded the Regenestem Networks presence to 20 countries, adding new state-of-the-art regenerative medicine facilities to the company's growing global presence.

Regenestem offers stem cell treatments to help with a variety of diseases and conditions including arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes, and pain due to injuries at various facilities worldwide. Regenestem Veracruz will have an international staff experienced in administering the leading cellular therapies available.

Regenestem is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Regenestem clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.

The Global Stem Cells Group and Regenestem are committed to the highest of standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

For more information, visit the Regenestem Network website, email info(at)regenstem(dot)com, or call 305-224-1858.

About Regenestem:

Go here to see the original:
Regenestem Network, a division of Global Stem Cells Group, Announces Launch of New Stem Cells and Regenerative ...

The International Society for Stem Cell Research's McEwen Award recipient Hans Clevers extends breakthrough work

CHICAGO -- The International Society for Stem Cell Research (ISSCR) has awarded Dr. Hans Clevers, senior author on two important papers published recently in the scientific journal Cell, the society's McEwen Award for Innovation. The papers describe the development of a culturing system for human liver stem cells, as well as stem cells from pancreatic cancer, discoveries with the potential to revolutionize liver transplantation and aid in the fight against pancreatic cancer, respectively.

Clevers is a professor at the Hubrecht Institute and president of the Royal Netherlands Academy of Arts and Sciences. He shares the McEwen Award for Innovation with Dr. Irving Weissman, Stanford School of Medicine, for the identification, prospective purification and characterization of somatic (adult) tissue-associated stem cells and advancement of this research toward clinical applications.

"These new discoveries by Hans Clevers extend the work for which he was awarded the McEwen Award, the ISSCR's most prestigious award," Dr. Rudolf Jaenisch, ISSCR president, said. "The innovative approach Dr. Clevers took in the gut has borne fruit and proven the basis of these significant advances in the liver and pancreas, which hold great promise for the study of and treatments for diseases impacting these organs."

Organoids

Until recently, it appeared impossible to keep healthy or diseased tissue from patients alive under laboratory conditions, let alone multiply it. However, in 2009, the research group headed by Clevers described a revolutionary culturing method that allowed the culturing of mini-guts from single mouse intestine stem cells. These organoids are functional miniature organs that can grow in tissue culture. The same research group now adds a culturing system for liver stem cells and stem cells from pancreatic cancer to their record. In the future, cultured stem cells could conceivably replace donor organs for transplantation. They also offer prospects for personalized medicine, the development of treatments specifically geared to individual patients.

Cultured Liver Stem Cells

The technology described in Cell can be used for the long-term replication in the laboratory of minute amounts of tissue harvested from a healthy or diseased liver. Over a period of four months, the equivalent of a full-grown liver can be cultured from a single liver stem cell. All analyses show that this cultured tissue is genetically the same as healthy liver tissue and is very stable.

The cultured human mini-livers have already been successfully transplanted in mice with liver damage. This is the first step toward using this cultured liver tissue to replace donor livers for transplantation. As such, this technology could solve the worldwide shortage of donor livers. Moreover, this technology offers future potential for personalized medicine. Organoids could, for instance, be grown from the tissue of patients suffering from genetic liver diseases, so that drugs could be tested on this patient material first, before being administered to the patients themselves. Examples of such diseases are alpha-1 antitrypsin deficiency and Alagille Syndrome.

Pancreatic Stem Cells

See the original post:
Scientists announce revolutionary culturing technique for liver and pancreas

Naples, Florida (PRWEB) January 23, 2015

The Miami Stem Cell Treatment Center announces a series of free public seminars on the use of adult stem cells for various degenerative and inflammatory conditions. They will be provided by Dr. Thomas A. Gionis, Surgeon-in-Chief and Dr. Nia Smyrniotis, Medical Director and Surgeon.

The first seminar will be held on Sunday, January 25, 2015, at 11:00am, 1:00pm and 3:00pm at the Hilton Naples, 5111 Tamiami Trail North, Naples, FL 34103. Please RSVP at (561) 331-2999.

The Miami Stem Cell Treatment Center (Miami; Boca Raton; Orlando), along with sister affiliates, the Irvine Stem Cell Treatment Center (Irvine; Westlake Villages, Ca.) and the Manhattan Regenerative Medicine Medical Group (Manhattan, New York), abide by approved investigational protocols using adult adipose derived stem cells (ADSCs) which can be deployed to improve patients quality of life for a number of chronic, degenerative and inflammatory conditions and diseases. ADSCs are taken from the patients own adipose (fat) tissue (found within a cellular mixture called stromal vascular fraction (SVF)). ADSCs are exceptionally abundant in adipose tissue. The adipose tissue is obtained from the patient during a 15 minute mini-liposuction performed under local anesthesia in the doctors office. SVF is a protein-rich solution containing mononuclear cell lines (predominantly adult autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important Growth Factors that facilitate the stem cell process and promote their activity.

ADSCs are the bodys natural healing cells - they are recruited by chemical signals emitted by damaged tissues to repair and regenerate the bodys injured cells. The Miami Stem Cell Treatment Center only uses Adult Autologous Stem Cells from a persons own fat No embryonic stem cells are used; and No bone marrow stem cells are used. Current areas of study include: Emphysema, COPD, Asthma, Heart Failure, Heart Attack, Parkinsons Disease, Stroke, Traumatic Brain Injury, Lou Gehrigs Disease, Multiple Sclerosis, Lupus, Rheumatoid Arthritis, Crohns Disease, Muscular Dystrophy, Inflammatory Myopathies, and degenerative orthopedic joint conditions (Knee, Shoulder, Hip, Spine).

For more information, or if someone thinks they may be a candidate for one of the adult stem cell protocols offered by the Miami Stem Cell Treatment Center, they may contact Dr. Gionis or Dr. Smyrniotis directly at (561) 331-2999, or see a complete list of the Centers study areas at: http://www.MiamiStemCellsUSA.com.

About the Miami Stem Cell Treatment Center: The Miami Stem Cell Treatment Center, along with sister affiliates, the Irvine Stem Cell Treatment Center and the Manhattan Regenerative Medicine Medical Group, is an affiliate of the California Stem Cell Treatment Center / Cell Surgical Network (CSN); we are located in Boca Raton, Orlando, Miami and The Villages (opening soon), Florida. We provide care for people suffering from diseases that may be alleviated by access to adult stem cell based regenerative treatment. We utilize a fat transfer surgical technology to isolate and implant the patients own stem cells from a small quantity of fat harvested by a mini-liposuction on the same day. The investigational protocols utilized by the Miami Stem Cell Treatment Center have been reviewed and approved by an IRB (Institutional Review Board) which is registered with the U.S. Department of Health, Office of Human Research Protection (OHRP); and our studies are registered with Clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH).

For more information, visit our websites: http://www.MiamiStemCellsUSA.com, http://www.IrvineStemCellsUSA.com , or http://www.NYStemCellsUSA.com.

Excerpt from:
The Miami Stem Cell Treatment Center Announces Adult Stem Cell Public Seminars in Naples, Florida

Researchers at the Stanford University School of Medicine have discovered the stem cell in mice that gives rise to bone, cartilage and a key part of bone marrow called the stroma.

In addition, the researchers have charted the chemical signals that can create skeletal stem cells and steer their development into each of these specific tissues. The discovery sets the stage for a wide range of potential therapies for skeletal disorders such as bone fractures, brittle bones, osteosarcoma or damaged cartilage.

A paper describing the findings will be published Jan. 15 in Cell.

"Millions of times a year, orthopedic surgeons see torn cartilage in a joint and have to take it out because cartilage doesn't heal well, but that lack of cartilage predisposes the patient to arthritis down the road," said Michael Longaker, MD, a professor of plastic and reconstructive surgery at Stanford and a senior author of the paper. "This research raises the possibility that we can create new skeletal stem cells from patients' own tissues and use them to grow new cartilage." Longaker is also co-director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine.

An intensive search

The researchers started by focusing on groups of cells that divide rapidly at the ends of mouse bones, and then showed that these collections of cells could form all parts of bone: the bone itself, cartilage and the stroma -- the spongy tissue at the center of bones that helps hematopoietic stem cells turn into blood and immune cells. Through extensive effort, they then identified a single type of cell that could, by itself, form all these elements of the skeleton.

The scientists then went much further, mapping the developmental tree of skeletal stem cells to track exactly how they changed into intermediate progenitor cells and eventually each type of skeletal tissue.

"Mapping the tree led to an in-depth understanding of all the genetic switches that have to be flipped in order to give rise to more specific progenitors and eventually highly specialized cells," said postdoctoral scholar Charles Chan, PhD, who shares lead authorship of the paper with postdoctoral scholar David Lo, MD, graduate student James Chen and research assistant Elly Eun Young Seo. With that information, the researchers were able to find factors that, when provided in the right amount and at the right time, would steer the development of skeletal stem cells into bone, cartilage or stromal cells.

"If this is translated into humans, we then have a way to isolate skeletal stem cells and rescue cartilage from wear and tear or aging, repair bones that have nonhealing fractures and renew the bone marrow niche in those who have had it damaged in one way or another," said Irving Weissman, MD, professor of pathology and of developmental biology, who directs the Stanford Institute for Stem Cell Biology and Regenerative Medicine. Weissman, the other senior author of the paper, also holds the Virginia and Daniel K. Ludwig Professorship in Clinical Investigation in Cancer Research.

Reprogramming fat cells

Excerpt from:
Stanford researchers isolate stem cell that gives rise to bones, cartilage in mice

MIAMI (PRWEB) January 14, 2015

Citing fast-paced growth and the need for more space to accommodate its expanding operations, Global Stem Cells Group CEO Benito Novas has announced plans to move the organizations headquarters from Sunrise, Florida to the Miami Lakes Corporate Center. The new location more than doubles the space for the international stem cell and regenerative medicine company's corporate offices.

Since opening in 2012 under the Regenestem brand, Global Stem Cells Group and its six operating companies have grown exponentially, establishing partnerships with stem cell clinics, hospitals, researchers and physicians in the Philippines, South America and Europe.

The new Global Stem Cells Group facility provides state-of-the-art space for our entire team to drive innovation through our research and development initiatives, and support partnering activities with our biotechnology products and education programs, Novas says. We now have the space to continue the fast-paced growth of our companies and advance the development of new stem cell and regenerative medicine technologies that will benefit patients worldwide.

The new corporate headquarters, scheduled to open January 15, 2015, are located in the Miami Lakes Corporate Center, 14750 NW 77th Court, Suite 304 Miami Lakes, FL 33016.

For more information visit the Global Stem Cells website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

See the original post:
Global Stem Cells Group to Move Headquarters to Larger Miami Lakes Office Complex

Contact Information

Available for logged-in reporters only

Newswise January 13, 2015 New York, NY Peter S. Kim has been named the Virginia and D.K. Ludwig Professor of Biochemistry at Stanford University School of Medicine. Established in 1994, Ludwig professorships have since been awarded to a total of 15 leading scientists at academic institutions affiliated with the six U.S.-based Ludwig Centers. With this appointment Kim also becomes a member of the Ludwig Center for Cancer Stem Cell Research and Medicine at Stanford.

Kims lab focuses on the mechanisms by which viral membranes fuse with cell membranes, which has to happen for the virus to invade its target cell. His team also studies how that process might be disrupted by small molecules and antibodies. Kims lab is, for example, using such studies to engineer antigens for a vaccine that might elicit antibodies that block a key step in HIVs invasion of its target cell. The strategies that he is developing could be applied to design new preventive and therapeutic vaccines for cancers. His lab is also developing methods to identify small molecules that bind tightly and very specifically to proteins that have so far proved resistant to targeting by typical drug-like molecules.

Kim joined Stanford University in February 2014 after a ten-year tenure as president of Merck Research Laboratories, Merck & Co., Inc. During this time he oversaw the development and FDA approval of Gardasil, the worlds first vaccine against HPV, the causative agent of cervical cancer. Kim began his academic career as a professor in the biology department at MIT, where he ultimately served as associate head. During his 16 years at MIT Kim was also an investigator of the Howard Hughes Medical Institute and a member of the Whitehead Institute for Biomedical Research.

We are very happy, and fortunate, to have Peter Kim back here at Stanford, where he began his graduate training, said Irv Weissman, director of the Ludwig Center for Cancer Stem Cell Research and Medicine at Stanford. Peter brings with him rare experience and new strategies for developing preventive tools and therapiesincluding immunotherapiesfor viral infections that cause, allow and/or infect cancers. His goals are in line with our mission, and his approaches complement our own efforts to recruit the immune system to attack cancer cells.

Kim has received numerous awards for his research and holds leadership positions at several academic and scientific institutions. He is a member of the National Academy of Sciences and the Institute of Medicine and a fellow of the American Academy of Arts and Sciences. He serves on the Scientific Review Board of the Howard Hughes Medical Institute, the External Scientific Advisory Board of the Harvard Program in Therapeutic Science, the Board of Scientific Governors of the Scripps Research Institute and the Scientific Advisory Working Group of the Vaccine Research Center, NIAID, NIH.

Kim joins four other Virginia and D.K. Ludwig Professors at Stanford: Lucy Shapiro, Irving Weissman, Sanjiv Sam Gambhir and Roeland Nusse.

# # #

About Ludwig Cancer Research Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer discoveries for more than 40 years. Ludwig combines basic research with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested more than $2.5 billion in life-changing cancer research through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers.

See more here:
Peter S. Kim Named the Virginia and D.K. Ludwig Professor of Biochemistry at Stanford

IMAGE:This is the cover for Stem Cells, Tissue Engineering and Regenerative Medicine. view more

Credit: World Scientific, 2015

In his latest book published by World Scientific, Professor David Warburton from The Saban Research Institute of Children's Hospital Los Angeles and the University of Southern California presents a collection of essays on the current state of the regenerative medicine and stem cell research field.

Entitled Stem Cells, Tissue Engineering and Regenerative Medicine, this up-to-date compendium surveys current issues in stem cell biology and regenerative medicine. Topics range from key concepts in regenerative medicine to the newest progenitor cell therapies for organ systems, to advice on how to set up a pluripotent stem cell laboratory.

Overviews of the most recent progress in stem cell research describe work that is in the pre-clinical pipeline from scientists working at The Saban Research Institute of Children's Hospital Los Angeles and colleagues around the world.

"The book addresses some of the big questions faced by researchers in the field of stem cell biology and regenerative medicine," said Professor Warburton. "Those of us working in this field in California are positively impacted by the critical funding provided by the citizens of the state through the California Institute for Regenerative Medicine. I believe this book shows that the hope behind CIRM - the hope that stem cells can really revolutionize medicine and human health - is fully justified."

A global collection of essays from collaborating investigators in Australia, Brazil, Iran, Taiwan and the United Kingdom, as well as across the United States. This book will describe diverse regenerative medicine solutions for airways, cancer, craniofacial structures, intestine, heart, kidney, liver, lung and nervous system. These advances are placed in the context of the overall field, providing an investigator-level overview which will be accessible to the educated scientific generalist as well as a college-educated readership, scientific writers, educators and professionals of all kinds.

###

Professor Warburton's research is supported by the California Institute for Regenerative Medicine, the National Institutes of Health: National Heart, Lung and Blood Institute, National Institute of Environmental Health Sciences, Fogarty International Center, National Institute of General Medical Sciences, The Pasadena Guild of Children's Hospital Los Angeles, The Santa Anita Foundation, The Webb Foundation, The Garland Foundation and anonymous venture philanthropy.

The book retails for US$155/ 102 (hardcover). More information on the book can be found at http://www.worldscientific.com/worldscibooks/10.1142/9212.

See the article here:
Renowned professor's book addresses stem cell biology & regenerative medicine

Tampa, FL (PRWEB) January 06, 2015

One million Americans experience acute myocardial infarctions, commonly known as a heart attack, each year and of those, approximately 300,000 to 500,000 individuals develop heart failure. A heart attack occurs when blood stops flowing properly to a part of the heart and the heart muscle is injured and can die because it is not receiving enough oxygen.

Cryo-Cell International has agreed to provide the Center with cord blood collections that have previously been donated to Cryo-Cell International by parents and designated for research use to advance regenerative medicine. These cord blood collections will allow the Centers scientists to continue to investigate the mechanisms whereby stem cells can be beneficial in limiting damage from heart attacks. A team at the Center, led by researcher and cardiology specialist, Robert J. Henning, M.D., has demonstrated in research animals that stem cells obtained from human umbilical cord blood can release a large number of biologically active growth factors and anti-inflammatory chemicals that can limit the substantial heart inflammation, cell injury and cell destruction that occurs with acute heart attacks, significantly reducing the effects of heart attacks, even when administered up to 24 hours after the heart attack.

We are making good progress in our studies thanks to the cord blood stem cells contributed by Cryo-Cell International, reports Henning.

Cryo-Cell International and others have demonstrated that human umbilical cord blood stem cells can be preserved for more than 20 years without loss of cell viability or potency. Consequently, parents who have the foresight to use cord blood banking services upon their babys birth can potentially use these cord blood stem cells years later to provide a regenerative treatment for a family member if an acute heart attack occurs. The Centers scientists hope to bring umbilical cord blood stem cell therapy to the treatment of patients who have experienced heart attacks within the next five years.

Heart disease is still the number one leading cause of death in the United States. We feel very fortunate that we can provide a valuable and consistent source of cord blood banked stem cells to the Center for Cardiovascular Research, said David Portnoy, Chairman and Co-CEO of Cryo-Cell International.

About Cryo-Cell International

Founded in 1989, Cryo-Cell International, Inc. is the world's first and most highly accredited private cord blood bank. More than 500,000 parents from 87 countries trust Cryo-Cell International to preserve their family members' stem cells. Cryo-Cell International's mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine. Cryo-Cell International operates in a facility that is FDA registered, cGMP-/cGTP-compliant and is licensed in all states requiring licensure. In addition to earning AABB accreditation for cord blood banking, Cryo-Cell International is also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for voluntarily adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. Cryo-Cell International is ISO 9001:2008 certified by BSI, an internationally recognized, quality assessment organization. Cryo-Cell International is a publicly traded company, OTCQB: CCEL. For more information, please visit http://www.Cryo-Cell.com.

About the University of South Florida Center for Cardiovascular Research

The University of South Florida Morsani College of Medicines Cardiovascular Services Research Unit has been in existence for almost 20 years and evaluates pharmacotherapeutic agents and the latest treatment and devices for cardiovascular disease.

Continued here:
Cord Blood Banking Leader, Cryo-Cell International, Continues to Support the Advancement of Regenerative Medicine